Electromed (NYSE:ELMD) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Electromed (NYSE:ELMD) from a strong-buy rating to a buy rating in a report published on Thursday.

Electromed Price Performance

Shares of NYSE ELMD opened at $29.77 on Thursday. The stock has a market capitalization of $251.79 million, a price-to-earnings ratio of 41.35 and a beta of 0.31. The firm’s 50 day simple moving average is $28.70 and its 200-day simple moving average is $21.58. Electromed has a 12 month low of $9.90 and a 12 month high of $31.88.

Electromed (NYSE:ELMD) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.03 by $0.13. The company had revenue of $14.67 million for the quarter. Electromed had a net margin of 11.34% and a return on equity of 15.32%.

Insider Buying and Selling

In related news, Director Andrew Summers sold 12,731 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $29.98, for a total value of $381,675.38. Following the completion of the sale, the director now owns 165,755 shares of the company’s stock, valued at approximately $4,969,334.90. The trade was a 7.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.00% of the stock is currently owned by insiders.

Institutional Trading of Electromed

Institutional investors have recently modified their holdings of the stock. Barclays PLC purchased a new position in Electromed in the 3rd quarter valued at about $215,000. Wilmington Savings Fund Society FSB purchased a new stake in Electromed during the 3rd quarter worth approximately $226,000. Marshall Wace LLP acquired a new position in shares of Electromed during the second quarter valued at approximately $256,000. Walleye Capital LLC purchased a new position in shares of Electromed in the third quarter valued at approximately $274,000. Finally, Navellier & Associates Inc. acquired a new stake in shares of Electromed in the third quarter worth approximately $368,000. Institutional investors and hedge funds own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.